Skip to Content
Merck
All Photos(1)

Documents

D1010000

Dibutyl phthalate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

n-Butyl phthalate, DBP, Phthalic acid dibutyl ester

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
C6H4-1,2-[CO2(CH2)3CH3]2
CAS Number:
Molecular Weight:
278.34
Beilstein:
1914064
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

vapor density

9.6 (vs air)

vapor pressure

1 mmHg ( 147 °C)

API family

dibutyl phthalate

autoignition temp.

756 °F

expl. lim.

0.47 %, 236 °F

manufacturer/tradename

EDQM

refractive index

n20/D 1.492 (lit.)

bp

340 °C (lit.)

mp

−35 °C (lit.)

density

1.043 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCCCOC(=O)c1ccccc1C(=O)OCCCC

InChI

1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3

InChI key

DOIRQSBPFJWKBE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Plasticizer

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Pictograms

Health hazardEnvironment

Signal Word

Danger

Hazard Statements

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

367.7 °F - open cup

Flash Point(C)

186.5 °C - open cup


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Dion H Zappe et al.
Journal of hypertension, 33(2), 385-392 (2014-09-27)
Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. We compared the antihypertensive effects of morning (a.m.) and evening
Harpreet Bhatia et al.
Aquatic toxicology (Amsterdam, Netherlands), 149, 103-115 (2014-03-01)
Phthalic acid esters (PAEs) are a class of synthetic industrial chemicals commonly found in the aquatic environment worldwide. PAEs have been recognised as anti-androgens in male mammals but little is known about their endocrine disrupting effects in fish. This study
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service